TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced exposure to anticholinergics
Description: Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced exposure to anticholinergics
Description: Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced exposure to benzodiazepines
Description: Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced exposure to benzodiazepines
Description: Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
Study: NCT03380403

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: clinical treatment of infected diabetic foot
Study: NCT02767154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-Acetate and Mannitol
Description: Currently clinic standard for priming the CPB circuit.
Study: NCT04325763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB2450(blank)
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anlotinib(blank)
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib(blank)
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study: NCT02885181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9876
Description: One tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9876
Description: One tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Two tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9876 placebo
Description: One tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9876 placebo
Description: One tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Two tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Two tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: Two tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Study: NCT03380403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: antibiotics and or surgical debridment
Study: NCT01991769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 47 min moderate intensity training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 47 min moderate intensity training
Study: NCT01749800

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham GVS
Description: Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham GVS
Description: Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Armeo Spring
Description: A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armeo Spring
Description: A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
Study: NCT03477669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chamomile/probiotic arm
Description: Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of chamomile/probiotic arm
Description: Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
Study: NCT01991769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise healthy volunteers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise healthy volunteers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control; no exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control; no exercise training
Study: NCT03305575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia.
Study: NCT04214041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-epithelial connective tissue graft
Description: A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
Study: NCT02377271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: treatment by bosentan or placebo is randomized , 125 mg twice a day
Study: NCT02034201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00794378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine (Clarinex)
Description: Each subject received 5 mL of desloratadine syrup one time
Study: NCT02377271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment by bosentan or placebo is randomized
Study: NCT00794378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Each subject received 5 mL of cetirizine syrup
Study: NCT03111589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
Study: NCT03598283

Intervention type: DEVICE
Intervention: Ultrasound/transient elastography
Description: The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
Study: NCT03111589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
Study: NCT01747044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 100mg/day
Study: NCT03111589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
Study: NCT01747044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01691339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Description: 0.5 mL, Intramuscular
Study: NCT02456441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
Study: NCT02997774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooler dialysis
Description: Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dialysis
Description: Having dialysis at a standard temperature (36.5 degrees Celsius)
Study: NCT01870791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Weekly omegaven infusion in combination with EOX chemotherapy
Study: NCT04660877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheddar Cheese
Description: 20g of protein from cheddar cheese

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk
Description: 20g of protein from milk
Study: NCT03794297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03639987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study: NCT02885181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Study: NCT03639987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03232632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 18 F-Flutemetamol
Description: PET with 18 F-Flutemetamol (Vizamyl ®)
Study: NCT01769482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01686100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No touch technique
Description: The vein graft is harvested with its surronding tissues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: The vein graft is stripped from its surrounding tissues.
Study: NCT03048409

Intervention type: OTHER
Intervention: Enteral Formula
Description: Enteral feeding with a peptide-based formula.
Study: NCT05024617

Intervention type: OTHER
Intervention: conservative treatment
Description: All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
Study: NCT03446612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside
Description: Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-N-monomethyl arginine acetate (L-NMMA)
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-N-monomethyl arginine acetate (L-NMMA)
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
Study: NCT00571519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone HCl
Description: 0.5 mg tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.0 mg tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.5 mg tablets administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets matching rivoglitazone tablets administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 15 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 30 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl 45 mg
Description: 45 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules for pioglitazone administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.
Study: NCT02422589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study: NCT03470168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygenation Therapy
Description: Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normobaric Oxygenation therapy
Description: Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
Study: NCT00571519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.
Study: NCT01902693

Intervention type: OTHER
Intervention: No intervention for this study
Description: No intervention